Navigation Links
OncoGenex Pharmaceuticals Files Shelf Registration Statement
Date:6/26/2009

iming of these activities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the risks associated with obtaining partnership and/or funding from third parties or completing a financing necessary to support the costs and expenses of Phase 3 clinical trials, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, except as required by applicable securities laws.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
4. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
5. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
6. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
7. OncoGenex Reports First Quarter Financial Results
8. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
9. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
10. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
11. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... Proove Biosciences , the commercial and ... a new genetic test built upon research from their ... will provide physicians with an objective way to ... are stratified between individuals. With this new test, physicians ... a genetic predisposition that will affect their pain tolerance. ...
(Date:9/30/2014)... Hungary , September 30, 2014 ... and intuitive browsing of chemistry in documents ... chemistry software solutions and consulting services for life ... chemical information and generate Markush structures from documents. ... an organizations intellectual property, however generating and understanding ...
Breaking Biology Technology:Taking thin films to the extreme 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2
... , M. Adams ... NJ, US, , ... DNA and sequencing template preparation needs. A combination of these kits with the Genesis ... high-throughput DNA preparation. , ...
... <P , ,>O. Rönn 1 , M. Landström 2 , A. Edman-Örlefors 1 ... 1 GE Healthcare, Uppsala, Sweden , ... Research, Uppsala, Sweden , , ... proteins at picogram levels, with linearity over 3.6 orders of magnitude. Two antigens ...
... , ... assay • LEADseeker • SPA Imaging Beads , ... biogenic amine that plays important pathophysiological roles in central and peripheral tissues. ... that characterize allergic responses (1).The function of histamine is mediated via four ...
Cached Biology Technology:Automation of TempliPhi and GenomiPhi DNA Amplification Kits on the Genesis Freedom Robotic Sample Processor 2Automation of TempliPhi and GenomiPhi DNA Amplification Kits on the Genesis Freedom Robotic Sample Processor 3Detection and quantitation of low-abundant proteins with ECL Plex fluorescent Western blotting 2Detection and quantitation of low-abundant proteins with ECL Plex fluorescent Western blotting 3Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 2Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 3Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 4Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 5
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... available in German . ... response to risky situations such as exposure to predators. ... found in a long-term study on different populations of ... rate and ambient temperature. High metabolic rates and low ... these scenarios birds were more likely to approach potential ...
(Date:9/30/2014)... Ill. (September 30, 2014) People who suffer from ... do to control their asthma besides properly taking medications ... new article in the Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), asthma sufferers ... their lifestyle. The woman described in the Annals article ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... Researchers at the Tufts University School of Engineering ... first large area metamaterial structures patterned on implantable, ... July 21, 2010, in the journal Advanced ... development of a new class of metamaterial-inspired implantable ...
... 2010 How toxic, blue-green algae out-compete other organisms ... so doing proliferate dangerously in freshwater bodies -- has ... of Jerusalem. In general, the increasing occurrence ... is a matter of growing international concern due to ...
... Hematopoietic stem cells (HSCs) have two unique abilities that ... into any kind of blood cell, which enables them to ... these qualities to a distinct locale or niche within the ... and function of the niche-forming constituents have not been clearly ...
Cached Biology News:Implantable silk metamaterials could advance biomedicine, biosensing 2Implantable silk metamaterials could advance biomedicine, biosensing 3How algae 'enslavement' threatens freshwater bodies described by Hebrew University researcher 2Researchers find that one type of stem cell creates a niche for another type in bone marrow 2Researchers find that one type of stem cell creates a niche for another type in bone marrow 3
... lyophilization stabilizer is designed to stabilize ... for long-term storage. There are ... It is a convenient 10 ... and is superior to other traditional ...
... Techne TC-512 is the only Gradient thermal cycler ... the touch of a screen. ,Wide linear ... the market, with an amazing range of,30C. Protocols ... , TouchScreen - The Touchgene Gradient incorporates a ...
... The Freedom EVO Clinical is Tecans open ... to enhance quality, safety and performance in ... Safety is provided by flexible barcode reading ... to mention that the system complies with ...
Request Info...
Biology Products: